Menu

BeyondSPX has rebranded as EveryTicker. We now operate at everyticker.com, reflecting our coverage across nearly all U.S. tickers. BeyondSPX has rebranded as EveryTicker.

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
NVO Novo Nordisk A/S
At-home administration devices (auto-injector devices) for GLP-1 therapies are part of Novo Nordisk’s delivery platform.
$180.05B
$40.51
-1.04%
TAK Takeda Pharmaceutical Company Limited
ENTYVIO Pen demonstrates the use of auto-injector devices for at-home administration of biologics.
$55.67B
$17.82
+0.25%
BDX Becton, Dickinson and Company
BD develops auto‑injector devices (wearable injectors) for home/at‑home administration of biologics.
$45.25B
$158.53
+2.40%
ROIV Roivant Sciences Ltd.
Auto-injector devices enabling at-home administration for IMVT-1402, fitting Auto-Injector Devices.
$20.75B
$29.80
+2.11%
WST West Pharmaceutical Services, Inc.
Auto-Injector Devices are a key product category in West's GLP-1 and other injectable platforms.
$19.69B
$273.73
+1.45%
ATR AptarGroup, Inc.
Aptar has auto-injector devices/platforms for at-home administration of injectable therapies.
$8.57B
$130.68
+1.86%
HALO Halozyme Therapeutics, Inc.
Halozyme is expanding its portfolio of auto-injector devices to enable at-home/self-administration of therapies.
$8.15B
$69.29
+3.98%
STVN Stevanato Group S.p.A.
Develops and manufactures Auto-Injector Devices for at-home/self-administration of injectable therapies.
$4.70B
$15.59
+3.73%
AMRX Amneal Pharmaceuticals, Inc.
DHE autoinjector (Brekiya) approval signals involvement in auto-injector device delivery systems.
$4.37B
$13.90
+6.19%
KE Kimball Electronics, Inc.
Auto-injector devices represent a differentiated medical device assembly capability.
$652.51M
$26.83
+1.48%
SCPH scPharmaceuticals Inc.
Auto-Injector Devices reflect the SCP-111 autoinjector program for at-home administration.
$299.33M
$5.67
ASRT Assertio Holdings, Inc.
Otrexup is an auto-injector device, fitting the Auto-Injector Devices category.
$115.57M
$18.02

Loading company comparison...

Loading research report...

AMRX Amneal Pharmaceuticals, Inc.

Amneal Expands into Respiratory Market with Two New Generic Inhalers

Apr 14, 2026
NVO Novo Nordisk A/S

Novo Nordisk Partners with OpenAI to Accelerate Drug Development and Operational Efficiency

Apr 14, 2026
NVO Novo Nordisk A/S

EMA Approves Wegovy Injection for 48‑Hour Room‑Temperature Storage, Enhancing Distribution Flexibility

Apr 10, 2026
AMRX Amneal Pharmaceuticals, Inc.

Amneal Launches First Generic Bimatoprost Ophthalmic Solution

Apr 09, 2026
ATR AptarGroup, Inc.

Aptar Digital Health Partners with Enable Injections to Deliver Companion Digital Solution for enFuse® System

Apr 09, 2026
BDX Becton, Dickinson and Company

BD Secures CE Mark for Liverty™ TIPS Stent Graft, Expanding EU Interventional Portfolio

Apr 09, 2026
BDX Becton, Dickinson and Company

BD Launches HemoSphere Stream™ Module for Continuous Non‑Invasive Blood‑Pressure Monitoring

Apr 07, 2026
HALO Halozyme Therapeutics, Inc.

Halozyme and Vertex Forge Exclusive Hypercon Collaboration to Expand Small‑Volume Biologic Delivery

Apr 07, 2026
NVO Novo Nordisk A/S

Novo Nordisk Launches Higher‑Dose Wegovy HD Injection Nationwide

Apr 07, 2026
BDX Becton, Dickinson and Company

BD Launches AI‑Enabled Medication Dispensing System and Connected Care Platform in Europe

Apr 02, 2026
NVO Novo Nordisk A/S

NICE Endorses Wegovy for Cardiovascular Risk Reduction, Expanding NHS Access to 1.2 Million Patients

Apr 01, 2026
NVO Novo Nordisk A/S

Novo Nordisk Launches Discounted Wegovy Subscription Program for Self‑Pay Patients

Mar 31, 2026
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Opens 165,000‑Square‑Foot Dublin Facility to Expand High‑Volume Injectable Capacity

Mar 31, 2026
NVO Novo Nordisk A/S

Novo Nordisk Secures FDA Approval for First Once‑Weekly Basal Insulin, Awiqli

Mar 27, 2026
TAK Takeda Pharmaceutical Company Limited

Supreme Court Allows Takeda Actos Racketeering Lawsuit to Proceed

Mar 24, 2026
NVO Novo Nordisk A/S

Novo Nordisk Launches DKK 15 Billion Share Repurchase Programme to Return Capital to Shareholders

Mar 23, 2026
ATR AptarGroup, Inc.

AptarGroup Expands Virus‑Protection Portfolio with New Collaboration in INNA‑051 Phase II Study

Mar 20, 2026
NVO Novo Nordisk A/S

Novo Nordisk Secures FDA Approval for Higher‑Dose Wegovy (Semaglutide 7.2 mg)

Mar 20, 2026